Penumbra Inc. (PEN) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, PEN carries an RQD score of 57, a letter grade of D+, and the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are scored as follows:

• Fundamental Cash Engine: 13 / 20 (ROIC 10.6%; FCF yield 1.38%). Returns on capital are present, but the free-cash-flow yield of 1.38% is thin relative to the $12.68B market cap, meaning a prospective investor is paying a high price for each dollar of cash generated.
• Whale 13F Flow: 11 / 20 (institutional accumulation and options positioning). This pillar is below midpoint, indicating institutional positioning provides only modest support in the source data.
• Insider Conviction: 8 / 20 (SEC Form 4 and Congressional PTR cluster flow). This is the weakest pillar, signaling limited insider or political-disclosure conviction behind the stock.
• Macro Regime Fit: 10 / 20 (Beta 0.91; sector sensitivity). A beta below 1.0 suggests lower-than-market price sensitivity, but the score reflects limited regime-fit benefit.
• Forensic Balance Sheet: 15 / 20 (Altman Z 21.05; Piotroski F 9/9; Debt/Equity 0.12). This is the strongest pillar: the forensic metrics point to a financially sound balance sheet and clean accounting signals.

Investor implications: the rating's upside driver is the balance-sheet strength and high-quality forensic profile. The valuation tradeoff is significant: the market data shows a P/E (TTM) of 71.4, forward P/E of 60, and EV/EBITDA of 52, which leaves limited margin for error if growth or cash generation disappoints. The low FCF yield (1.38%) and weak insider and institutional conviction scores reinforce the rating's caution. Taken together, the source data describes a financially sturdy company priced richly, with weak conviction signals, which is why the framework's verdict leans toward trimming rather than accumulating.

Penumbra Inc. (PEN) is a NYSE-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry, per the company profile. Beyond its sector and industry classification, the source data does not describe its products, customers, or revenue model. Not available in source data for detailed product and customer description. The company's reported revenue, gross margin of 67.1%, and operating margin of 13.5% are presented in the sections below.

Per the SEC financials, revenue grew from $1058.5M (FY 2023) to $1403.7M (FY 2025), and net income moved from $14.0M in FY 2024 to $177.7M in FY 2025. Per the market data, gross margin is 67.1%, operating margin 13.5%, and net margin 12.7%, with ROIC at 10.6%. Per the Roarable RQD rating, the Altman Z-Score is 21.05, the Piotroski F-Score is 9/9, and Debt/Equity is 0.12. The FY 2023 debt figure of $1632.2M is markedly higher than the FY 2024 and FY 2025 figures, a discontinuity the source data does not explain.

The news wire contains five items, all relating to PEN:

• Market wire (YELLOW): A Yahoo! Finance Canada report covering market action, institutional positioning, and fundamental catalysts.
• Market wire (YELLOW): A Yahoo Finance headline framing PEN's stock as facing "Q3 Earnings Valuation Scrutiny."
• Market wire (YELLOW): A Simply Wall St piece asking whether valuation is justified as "STORM PE" data strengthens the recovery story.
• Market wire (YELLOW): A Stock Titan report stating revenue rose 15.6% while quarterly profit moved the other way.
• Market wire (YELLOW): A Yahoo Finance headline questioning whether clinical data puts valuation back in focus.
• Catalyst (GREEN): A Simply Wall St piece covering Q3 growth and FDA clearance, asking whether upside is already priced in.

Risk watch items: the valuation-scrutiny headlines and the quarterly profit divergence noted by the Stock Titan report. Proprietary signals: none. Per the Butterfly Supply-Chain Graph, no proprietary signals are recorded.

• What drove the revenue-versus-profit divergence cited in the Stock Titan report, and how does it reconcile with FY 2025 net income of $177.7M?
• Why does reported debt fall from $1632.2M in FY 2023 to $172.0M in FY 2024, and what explains the missing FY 2023 cash figure?
• What products, customers, and revenue streams make up the reported revenue base?
• What specific clinical or FDA events are referenced in the news wire, and what is their expected financial impact?
• What are the current analyst consensus rating and price targets, and how do they compare with the 321.97 price?